PL2662091T3 - Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych - Google Patents

Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych

Info

Publication number
PL2662091T3
PL2662091T3 PL13164403T PL13164403T PL2662091T3 PL 2662091 T3 PL2662091 T3 PL 2662091T3 PL 13164403 T PL13164403 T PL 13164403T PL 13164403 T PL13164403 T PL 13164403T PL 2662091 T3 PL2662091 T3 PL 2662091T3
Authority
PL
Poland
Prior art keywords
methods
same
inflammatory diseases
treat inflammatory
selectin antibodies
Prior art date
Application number
PL13164403T
Other languages
English (en)
Inventor
Rodger P. Mcever
Richard Alvarez
Ziad S. KAWAR
Original Assignee
Novartis Ag
Oklahoma Medical Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Oklahoma Medical Res Foundation filed Critical Novartis Ag
Publication of PL2662091T3 publication Critical patent/PL2662091T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13164403T 2006-12-01 2007-11-30 Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych PL2662091T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87217006P 2006-12-01 2006-12-01
EP13164403.1A EP2662091B1 (en) 2006-12-01 2007-11-30 Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
PCT/US2007/024692 WO2008069999A2 (en) 2006-12-01 2007-11-30 Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
EP07867601A EP2097105A4 (en) 2006-12-01 2007-11-30 ANTI-P SELEKTIN ANTIBODIES AND METHOD FOR THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES

Publications (1)

Publication Number Publication Date
PL2662091T3 true PL2662091T3 (pl) 2019-05-31

Family

ID=39492818

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13164403T PL2662091T3 (pl) 2006-12-01 2007-11-30 Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych

Country Status (11)

Country Link
US (2) US8377440B2 (pl)
EP (3) EP3501538A1 (pl)
CY (2) CY1121072T1 (pl)
DK (1) DK2662091T3 (pl)
ES (1) ES2699273T3 (pl)
HU (3) HUE041957T2 (pl)
LT (2) LT2662091T (pl)
PL (1) PL2662091T3 (pl)
PT (1) PT2662091T (pl)
SI (1) SI2662091T1 (pl)
WO (1) WO2008069999A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
EP3222635A1 (en) * 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
US10206941B2 (en) 2013-07-09 2019-02-19 President And Fellows Of Harvard College Venule endothelial cell genes and uses thereof
WO2015006501A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US20200087403A1 (en) 2017-03-15 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
MX421249B (es) * 2017-05-10 2025-02-10 Wistar Inst Constructos de anticuerpos de ácidos nucleicos optimizados
ES2911600T3 (es) 2017-06-20 2022-05-20 Inst Nat Sante Rech Med Métodos para identificar si pacientes con insuficiencia cardiaca aguda descompensada (ICAD) presentan un estado hipercoagulable
CN107299112A (zh) * 2017-06-22 2017-10-27 广东药科大学 一种炎症分子（psgl‑1）缺失的脂代谢异常模型的构建及其应用
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
RU2020132460A (ru) 2018-03-08 2022-04-08 Новартис Аг Применение антитела к p-селектину
US20220306749A1 (en) 2019-06-07 2022-09-29 Novartis Ag Use of an Anti-P-selectin Antibody
EP3790545A4 (en) 2019-07-17 2021-07-28 Emmaus Medical, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF SICKLE CLEANEMIA AND THALASSEMIA
AU2020326490A1 (en) * 2019-08-08 2022-03-24 Novartis Ag Use of the anti-P-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease
WO2021087050A1 (en) 2019-10-30 2021-05-06 Novartis Ag Crizanlizumab containing antibody formulation
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
JP7846007B2 (ja) 2019-12-18 2026-04-14 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993006863A1 (en) 1991-09-30 1993-04-15 Biogen, Inc. Inhibition of vascular narrowing using anti-padgem antibodies
EP0639224B1 (en) 1992-04-30 2000-06-28 Genentech, Inc. Lectin domain variants of selectin
ATE237353T1 (de) 1992-05-05 2003-05-15 Aeres Biomedical Ltd Antikörper gegen p-selectin und ihre verwendung
US6033667A (en) 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
WO1994025067A1 (en) 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
ATE316385T1 (de) * 1994-06-03 2006-02-15 Cbr Inst For Biomed Res Inc Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
EP1289552B1 (en) 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2003230985A1 (en) * 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
HUE035898T2 (en) * 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
PL2662091T3 (pl) * 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
AU2009246166B2 (en) 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
EP3222635A1 (en) 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification

Also Published As

Publication number Publication date
CY1121072T1 (el) 2019-12-11
EP2662091A2 (en) 2013-11-13
US9556266B2 (en) 2017-01-31
EP3501538A1 (en) 2019-06-26
SI2662091T1 (sl) 2019-01-31
EP2662091B1 (en) 2018-08-22
LT2662091T (lt) 2018-12-10
CY2021009I1 (el) 2021-10-15
LTPA2021506I1 (lt) 2021-05-10
WO2008069999A3 (en) 2008-12-04
US20110243926A1 (en) 2011-10-06
US8377440B2 (en) 2013-02-19
CY2021009I2 (el) 2021-12-31
PT2662091T (pt) 2018-12-03
HUS2100011I1 (hu) 2021-05-28
DK2662091T3 (en) 2018-12-17
ES2699273T3 (es) 2019-02-08
US20140072551A1 (en) 2014-03-13
EP2662091A3 (en) 2014-03-12
EP2097105A4 (en) 2010-09-15
WO2008069999A2 (en) 2008-06-12
HUE041957T2 (hu) 2019-06-28
LTC2662091I2 (lt) 2022-10-10
EP2097105A2 (en) 2009-09-09
HUS2100015I1 (hu) 2021-05-28

Similar Documents

Publication Publication Date Title
HUS2100015I1 (hu) Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
ZA200903775B (en) Human monoclonal antibodies to BTLA and methods of use
ZA201000545B (en) Human antibodies to human cd20 and method of using thereof
IL248723A0 (en) Specific antibodies against the bcr complex and methods of using them
EP2315780B8 (en) Compositions and methods of use for therapeutic antibodies
SI3002298T1 (sl) Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe
PT2373691T (pt) Anticorpos anti-fxi e métodos de utilização
IL211623A0 (en) Anti-notch2 antibodies and methods of use
EP2185719A4 (en) RANTES ANTIBODIES AND METHOD FOR THEIR USE
IL196920A0 (en) Compositions and methods using anti-csi antibodies to treat multiple myeloma
EP2021455A4 (en) SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
EP2195025A4 (en) THERAPEUTIC ANTIBODY PURIFICATION METHOD AND METHOD OF USE
IL232011A0 (en) Antibodies to 7egfl and methods of using them
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
ZA200807225B (en) Antibodies to EGFL7 and methods for their use
HK1135710A (en) Human monoclonal antibodies to btla and methods of use
IL202502A0 (en) Agents for the treatment of inflammatory diseases and methods of using same
HK1140682A (en) Therapeutic antibody purification method and method of use